Biotechnology News and Research

RSS

Survey: 67% of pharma and biotech companies outsource more than half of all clinical trials

Driving clinical development and speeding time to market through effective relationship management will be two of the key themes discussed at Pharma IQ's 2nd Annual Global Clinical Outsourcing Forum this May.

23 Feb 2011

PPD, Elan establish strategic collaboration to execute clinical programs

Elan, plc and PPD, Inc. today announced they have formed a global business collaboration focused on the advancement, progression and execution of Elan's development portfolio.

23 Feb 2011

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

USPTO issues patent to Silence Therapeutics' siRNA technology

Silence Therapeutics plc announces the issuance of United States patent 7,893,245, titled "Interfering RNA Molecules," by the United States Patent and Trademark Office.

23 Feb 2011

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

China Cord Blood announces formation of Zhejiang Lukou Biotechnology

China Cord Blood Corporation, the first and largest cord blood banking operator in China, today announced the formation of Zhejiang Lukou Biotechnology Co., Ltd., an indirect non-wholly owned subsidiary with the Zhejiang Provincial Blood Center, pursuant to the Company's framework agreement announced in September 2010.

22 Feb 2011

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Vical Incorporated announced today that the company has extended its relationship with the U.S. Naval Medical Research Center to develop its platform technology for the rapid development and production of vaccines against emerging infectious diseases.

22 Feb 2011

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin(r) program, currently under evaluation for the treatment of cancer.

22 Feb 2011

Best Medical Belgium to purchase Nordion's Belgian operations

Nordion Inc., a leading provider of products and services to the global health science market, today announced it has signed a share purchase agreement (SPA) with Best Medical Belgium (Best Medical) for the divestiture of the Company's Belgian operations, MDS Nordion S.A. Pursuant to the SPA, Best Medical will acquire all of Nordion's Belgian operations with the exception of the TheraSphere® business.

21 Feb 2011

Sheffield Bio-Science forms strategic alliance with Wockhardt to strengthen cell culture media portfolio

Sheffield Bio-Science, a Kerry Group Business, has formed a strategic global sales, marketing and development alliance with Wockhardt Ltd. Under this partnership, Sheffield Bio-Science will be the Exclusive Global Sales and Distribution Partner for recombinant insulin manufactured by global Indian biotech Wockhardt. According to estimates, the potential in cell culture markets is around US$ 50 million.

21 Feb 2011

New blood pressure measurement device may enable doctors to treat patients more effectively

In a major scientific breakthrough, a new blood pressure measurement device is set to revolutionise the way patients' blood pressure is measured.

20 Feb 2011

Slime of starfish may hold a clue for treating inflammatory diseases

Starfish have arms, spines and a mouth on the underside of its body. But what scientists are finding really interesting is the sticky goo which is secreted when the Starfish feels threatened. The slime contains properties which may prove invaluable in treating certain kinds of inflammatory illnesses.

20 Feb 2011

Artificial blood vessel could be available ‘off the shelf’ soon

Soon artificial blood vessels could be available ‘off the shelf’. This would mean that heart bypass patients would not have to be subjected to a minor operation to graft veins from other parts of their body. This would also make life easier for surgeons as well.

20 Feb 2011

Life Technologies announces winners of European Ion Torrent PGM Sequencer Grants Program

Life Technologies Corporation, today announced Dr. Angel Carracedo and Dr. Mark Pallen as the winners of the European Ion Torrent Personal Genome Machine (PGM™) Sequencer Grants Program.

19 Feb 2011

RegeneRx listed on MDB’s 'Best & Brightest' innovators for 2011

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has been included on MDB Capital Group's "Best & Brightest" innovators list of 150 companies for 2011. Criterion for inclusion is a ranking in the 90th percentile for technology leadership from more than 1,500 companies with U.S. patents granted, as rated by PatentVest®, MDB's proprietary, intellectual property (IP), business intelligence database.

19 Feb 2011

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix BioTherapeutics, Inc., announced today that new clinical data from the switchover trial of taliglucerase alfa in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 in Las Vegas, Nevada.

19 Feb 2011

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint.

19 Feb 2011

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has been ranked seventh in the biotech industry in Fast Company's annual list of the world's most innovative companies in 2011.

19 Feb 2011

Crustacean inspired technology leads to better calcium supplements

Ben-Gurion University of the Negev (BGU) researchers have developed a unique technology that stabilizes an otherwise unstable form of calcium carbonate. This mineral form provides significantly higher biological absorption and retention rates than other sources presently used as dietary calcium supplements.

19 Feb 2011

State roundup: Mass. cost control plan advances; Texas Senate's abortion bill vote; Miami's public hospital crisis

The governor of Massachusetts proposed changes on Thursday to the state's comprehensive healthcare program, one often seen as a prototype for national reforms, to attempt to bring rising costs under control. The plan would give the U.S. state more authority to scrutinize fees paid to hospitals and doctors, reform the current standard by which healthcare providers are compensated and enact medical malpractice reform.

19 Feb 2011

Biotechnology News and Research

Survey: 67% of pharma and biotech companies outsource more than half of all clinical trials

PPD, Elan establish strategic collaboration to execute clinical programs

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

USPTO issues patent to Silence Therapeutics' siRNA technology

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

China Cord Blood announces formation of Zhejiang Lukou Biotechnology

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Best Medical Belgium to purchase Nordion's Belgian operations

Sheffield Bio-Science forms strategic alliance with Wockhardt to strengthen cell culture media portfolio

New blood pressure measurement device may enable doctors to treat patients more effectively

Slime of starfish may hold a clue for treating inflammatory diseases

Artificial blood vessel could be available ‘off the shelf’ soon

Life Technologies announces winners of European Ion Torrent PGM Sequencer Grants Program

RegeneRx listed on MDB’s 'Best & Brightest' innovators for 2011

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

Crustacean inspired technology leads to better calcium supplements

State roundup: Mass. cost control plan advances; Texas Senate's abortion bill vote; Miami's public hospital crisis

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News